Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.
Dow Jones Pulls Back, Nvidia Stock helps Lift Nasdaq, S&P Flat In The Stock Market Today biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective hoisted by Canaccord Genuity Group from $20.00 to $24.00 in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock. HIMS has been the topic of several other research reports. Leerink Partnrs reiterated […]